Novavax is a US-based biotechnology company focused on the development of innovative vaccines that may help solve the world’s most pressing infectious disease challenges. Since our founding in 1987, we have been committed to developing novel products that leverage our proprietary recombinant nanoparticle vaccine technology to help prevent a broad range of infectious diseases. Our technology platform has the potential to produce highly immunogenic antigens, enabling the production of vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Novavax scientists bring years of integrity, study, and experience to the development of new and promising vaccines.